An international multidisciplinary expert panel recently published a new staging system for pediatric non-Hodgkin lymphoma. The proposed system characterizes 4 stages:
A single tumor, excluding mediastinum and abdomen
A single, extranodal tumor with regional node involvement, 2 or more nodal areas on the same side of the diaphragm, or a completely resectable primary gastrointestinal tract tumor, with or without associated mesenteric node involvement
2 or more extranodal tumors above and/or below the diaphragm, 2 or more nodal areas above and below the diaphragm, intra-abdominal and retroperitoneal disease, including liver, spleen, kidney, and /or ovary localizations, regardless of degree of resection, with or without involving associated mesenteric nodes that are completely resectable, any paraspinal or epidural tumor, and a single bone lesion with concomitant involvement of extranodal or nonregional nodal sites
Any of the stage I to III characteristics with initial involvement of the central nervous system, bone marrow, or both
Citation: Rosolen A, Perkins SL, Pinkerton CR, et al. Revised international pediatric non-Hodgkin lymphoma staging system. [published online ahead of print May 4, 2015]. J Clin Oncol. doi:10.1200/JCO.2014.59.7203.
This Week's Must Reads
Liquid biopsy aids assessment in advanced imatinib-resistant GIST, George S et al. ASCO 2018. Abstract 11511.
Rapid therapy changes fall short for metastatic GIST, Serrano-Garcia C et al. ASCO 2018, Abstract 11510.
Adjuvant doxorubicin and ifosfamide boost outcomes in soft tissue sarcomas, Pasquali S et al. ASCO 2018, Abstract 115118.
Estimated conditional OS shows upfront TKI benefit in mRCC, Kang M et al. J Urol. 2018 June 22. doi: 10.1016/j.juro.2018.06.030
Indolent course found in rare clear cell papillary RCC , Chen W-J et al. J Chinese Med Assoc. 2018 July 20 doi: 10.1016/j.jcma.2018.04.005
Must Reads in Lymphoma & Plasma Cell Disorders
Private Insurance Linked to Better Outcomes in Follicular Lymphoma, Goldstein JS et al. Blood. 2018 Jul 24. doi: 10.1182/blood-2018-03-839035.
PET/CT provides MCL staging information, Morgan R et al. Clin Lymphoma Myeloma Leuk. 2018 Jul 4. doi: 10.1016/j.clml.2018.06.024.
Durable responses seen from lisocabtagene in relapsed/refractory DLBCL, Abramson JS et al. ASCO 2018. Abstract 7505
Revised International Pediatric Non-Hodgkin Lymphoma Staging System, Expert panel publishes evidence-based system
Link Between Vitamin D and Lymphoma Survival, Analysis of patients in SWOG and LYSA trials